杜皮卢马布改善了患有异性食道炎的患者的组织病理特征:Liberty EoE TREET研究结果
Margaret H Collins1, Marc E Rothenberg2, Evan S Dellon3
1Division of Pathology and Laboratory Medicine, Cincinnati Hospital Medical Center, Cincinnati, Ohio.
Gastro hep advances
|June 9, 2025
概括
杜皮卢马布在24周之前显著改善了异性食管炎组织学分数,包括超出异性食管细胞计数峰值的异性食管细胞计数. 乙性食道炎 (EoE) 的这些改善持续到第52周.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 性食道炎 (EoE) 是一种慢性炎症状况.
- 组织病理学评估对于诊断和监测EoE至关重要.
- 乙性食道炎组织学评分系统 (EoEHSS) 评估了关键的组织病理特征.
研究的目的:
- 分析dupilumab对EoEHSS单个成分的影响.
- 调查EoE患者的组织病理学,内镜和症状测量之间的关系.
主要方法:
- 对LIBERTY EoE TREET试验数据的特异分析.
- 患者每周接受杜皮卢马布300毫克或安慰剂24周,随后进行延长阶段.
- 评估了EoEHSS得分的变化以及与其他措施的相关性.
主要成果:
- 与安慰剂相比,dupilumab在24周后改善了大多数EoEHSS等级/阶段组件.
- 改善在52周后持续,在切换到dupilumab的患者中,结果类似.
- 杜皮卢马布增加了EoE组织学缓解率,并显示了EoEHSS得分,高蛋白细胞数量峰值和内镜检测结果之间的相关性.
结论:
- 杜皮卢马布有效地改善了超越峰值乙氨基酸细胞计数的EoE组织病理特征.
- 这些组织学上的改善在持续治疗下持续下去.
- 杜比卢马布为管理EoE组织病理学提供了一个治疗选择.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
241
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
241
01:17Drugs for Treatment of Diarrhea-Predominant IBS
151
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
151